AbbVie (NYSE:ABBV) Shares Down 1% on Insider Selling

AbbVie Inc. (NYSE:ABBV) dropped 1% during trading on Monday after an insider sold shares in the company. The company traded as low as $223.23 and last traded at $227.7470. Approximately 7,788,091 shares were traded during trading, an increase of 8% from the average daily volume of 7,210,244 shares. The stock had previously closed at $230.11.

Specifically, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABBV. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 topline for ABBV‑295 (long‑acting amylin analog) showed clinically meaningful weight loss (~7.8%–9.8% at ~12 weeks) with a favorable tolerability profile, supporting continued development and adding a non‑incretin obesity program that could diversify AbbVie’s growth drivers. AbbVie Announces Positive Topline Results from a Phase 1…
• Positive Sentiment: Multiple outlets report ABBV‑295 produced up to ~9.8% weight loss in early data; AbbVie is positioning a ~$350M R&D/option bet behind an amylin program that could be complementary to existing incretin markets if later‑stage trials confirm efficacy and safety. AbbVie ties $350M amylin bet to almost 10% weight loss…
• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab (SKYRIZI) in Crohn’s disease support label expansion and incremental revenue opportunity for an already large immunology franchise. This reduces reliance on legacy products and strengthens AbbVie’s mid‑term growth profile. AbbVie Inc. (ABBV) Announces Positive Topline Results…
• Positive Sentiment: J.P. Morgan reiterated a Buy rating, and several market commentary pieces highlight AbbVie as a momentum/dividend name—these endorsements can support investor confidence while the pipeline readouts roll out. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Media and analyst pieces (Zacks, Yahoo) note increased investor attention and that the recent trial updates add context to valuation; useful for sentiment but not immediate catalysts unless followed by regulatory or commercial announcements. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: ICER announced a review of AbbVie’s Parkinson’s disease drug, which introduces potential pricing and reimbursement headwinds if ICER’s assessment is unfavorable—this can weigh on near‑term valuation even if clinical value is demonstrated. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: An AbbVie SVP sold roughly $1.22M of stock; insider sales are common but can be viewed negatively by traders as a short‑term signal. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

AbbVie Price Performance

The stock has a market capitalization of $402.70 billion, a price-to-earnings ratio of 96.50, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The stock has a 50 day moving average price of $224.72 and a 200-day moving average price of $224.21.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the firm posted $2.16 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ABBV. Corient Private Wealth LLC raised its position in AbbVie by 1.9% in the fourth quarter. Corient Private Wealth LLC now owns 2,390,243 shares of the company’s stock valued at $546,398,000 after purchasing an additional 43,777 shares during the period. Union Savings Bank acquired a new stake in shares of AbbVie in the fourth quarter valued at $1,079,000. Hsbc Holdings PLC raised its holdings in shares of AbbVie by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 4,064,980 shares of the company’s stock valued at $929,583,000 after buying an additional 92,544 shares during the period. Redwood Family Wealth LLC purchased a new stake in shares of AbbVie in the 4th quarter valued at $247,000. Finally, Cedarwood Wealth LLC acquired a new position in AbbVie during the 4th quarter worth about $430,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.